SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

GSK Says Ris-Rez Cut Osteosarcoma Progression or Death Risk 67%

GSK said its licensee Hansoh Pharmaceutical Group announced positive results for Ris-Rez in patients with relapsed osteosarcoma in China.

GSK

Related stories